Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Immatics US, Inc.
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
PACT Pharma, Inc.
Roger Williams Medical Center
Cancer Research UK